Ser635
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser635  -  TIF1A (human)

Site Information
DTHFRsPssSVGsPP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 11315000

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 1 , 3 ) , phospho-antibody ( 1 , 3 ) , phosphopeptide mapping ( 3 ) , western blotting ( 1 , 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
AMPKA1 (human) ( 3 ) , AMPKG2 (human) ( 1 )
Kinases, in vitro:
AMPKA1 (human) ( 3 )
Treatments:
acadesine ( 3 ) , glucose_starvation ( 3 ) , rapamycin ( 3 )

Downstream Regulation
Effects of modification on TIF1A:
activity, inhibited ( 3 )
Effects of modification on biological processes:
transcription, altered ( 3 ) , transcription, inhibited ( 1 )
Inhibit interaction with:
TAF1C (human) ( 3 )

References 

1

Cao Y, et al. (2017) Activation of γ2-AMPK Suppresses Ribosome Biogenesis and Protects Against Myocardial Ischemia/Reperfusion Injury. Circ Res 121, 1182-1191
28835357   Curated Info

2

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

3

Hoppe S, et al. (2009) AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc Natl Acad Sci U S A 106, 17781-6
19815529   Curated Info